Weekly Semaglutide vs. Daily Sitagliptin in T2D Patients
Nov 17, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences
One diabetes drug showed superior results for A1C reduction and weight loss.
Semaglutide (Ozempic®) is approved as a once-weekly GLP-1 RA for T2DM. It achieved its long-acting effect by adding two amino acids and one fatty acid chain, which leads to increased protein binding, thus increasing its half-life. Semaglutide has been proven to be effective in multiple studies compared to placebo and other antidiabetic therapies. It was reported to be effective in reducing A1C and BMI compared to the placebo. Additionally, it was reported that it had a significant reduction in the rate of major adverse cardiovascular events (MACE).
This study aims to compare semaglutide once weekly to sitagliptin once daily in a Chinese population, and to compare its findings to the SUSTAIN trials that included a global community....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.